The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Home » About NETRF » Board of Scientific Advisors
The Board of Scientific Advisors provides the scientific direction to the Neuroendocrine Tumor Research Foundation (NETRF) by offering programmatic advice, conducting peer-review of grant proposals to identify the best research, and serving as leaders in the field. The Board of Scientific Advisors comprises highly distinguished scientific and medical leaders who share a commitment to discovering a cure for neuroendocrine cancer. All members of the Board of Scientific Advisors are recognized experts in experimental and medical research, published authors in the top peer-reviewed medical journals, and leaders of collaborative research projects at top-ranked universities and institutes.
Education: The Pennsylvania State University (PhD)
Fellowships: The Pennsylvania State University, St. Jude Children’s Research Hospital
CO-CHAIR
Mireille Gillings Professor of Cancer Genomics – University of Exeter
Education: University College London (MD); University of London (PhD)
Post-Graduate Training: St. Bartholomew’s Hospital, Chelsea and Westminster, Charing Cross, Hammersmith and University College London Hospitals
Bernard and Mildred Kayden MGH Research Institute Chair Professor of Pathology, Harvard Medical School Massachusetts General Hospital
Education: University of Washington School of Medicine (MD, PhD)
Residency: Brigham and Women’s Hospital
Post-Doctoral Research: Harvard University
Director, Targeted Radionuclide Therapy, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center
Board Certification: Nuclear Medicine
Education: University of Pisa (MD); University of Groningen (PhD)
Residency: University of Pisa (Italy)
Fellowship: European Institute of Oncology (Italy)
Associate Professor of Medicine, Physician Lead for GI Clinical Research, Director, Neuroendocrine Tumor Program, Division of Hematology and Oncology, University of Pennsylvania,Perelman Center for Advanced Medicine
Board Certification: Internal Medicine and Medical Oncology
Education: Tufts University School of Medicine (MD)
Residency: University Hospitals Case Medical Center
Fellowships: University Hospitals Case Medical Center
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center
Board Certification: Medical Oncology and Internal Medicine
Education: Weill Cornell Medical College (MD)
Residency: Brigham and Women’s Hospital
Fellowship: MD Anderson Cancer Center
Director Hamon Center for Therapeutic Oncology Research Professor Internal Medicine & Pharmacology University of Texas Southwestern Medical Center, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research
Education: Stanford University Medical Center (MD)
Residency: Massachusetts General Hospital
Fellowship: National Institutes of Health